ES2032194T3 - Solubilizacion de agregados proteicos. - Google Patents

Solubilizacion de agregados proteicos.

Info

Publication number
ES2032194T3
ES2032194T3 ES198686309603T ES86309603T ES2032194T3 ES 2032194 T3 ES2032194 T3 ES 2032194T3 ES 198686309603 T ES198686309603 T ES 198686309603T ES 86309603 T ES86309603 T ES 86309603T ES 2032194 T3 ES2032194 T3 ES 2032194T3
Authority
ES
Spain
Prior art keywords
solubilization
protein
imperficiative
agent
source
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198686309603T
Other languages
English (en)
Spanish (es)
Inventor
Joseph John Patroni
Malcolm Roy Brandon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FIDELITY FOOD TECHNOLOGIES PTY Ltd
Original Assignee
FIDELITY FOOD TECHNOLOGIES PTY Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FIDELITY FOOD TECHNOLOGIES PTY Ltd filed Critical FIDELITY FOOD TECHNOLOGIES PTY Ltd
Application granted granted Critical
Publication of ES2032194T3 publication Critical patent/ES2032194T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445Plasmodium
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/61Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/10011Birnaviridae
    • C12N2720/10022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES198686309603T 1985-12-11 1986-12-10 Solubilizacion de agregados proteicos. Expired - Lifetime ES2032194T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPH381885 1985-12-11

Publications (1)

Publication Number Publication Date
ES2032194T3 true ES2032194T3 (es) 1993-01-16

Family

ID=3771404

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198686309603T Expired - Lifetime ES2032194T3 (es) 1985-12-11 1986-12-10 Solubilizacion de agregados proteicos.

Country Status (14)

Country Link
US (1) US4797474A (enExample)
EP (1) EP0226448B1 (enExample)
JP (1) JPH0660198B2 (enExample)
CN (1) CN86108729A (enExample)
AT (1) ATE76878T1 (enExample)
AU (1) AU597924B2 (enExample)
CA (1) CA1281849C (enExample)
DE (1) DE3685562T2 (enExample)
DK (1) DK171331B1 (enExample)
ES (1) ES2032194T3 (enExample)
GR (1) GR3004903T3 (enExample)
MY (1) MY101204A (enExample)
NO (1) NO864990L (enExample)
NZ (1) NZ218586A (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
AU612133B2 (en) * 1987-02-20 1991-07-04 Natinco Nv Production of proteins in active forms
CA1305285C (en) * 1987-04-21 1992-07-14 Malcolm Roy Brandon Production of proteins in active forms
US4931543A (en) * 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
US5654176A (en) * 1987-05-28 1997-08-05 Amrad Corporation Limited Fusion proteins containing glutathione-s-transferase
EP0295859B1 (en) * 1987-06-15 1994-11-17 Southern Cross Biotech Pty.Ltd. Production of proteins in active forms
AU609824B2 (en) * 1987-06-15 1991-05-09 Southern Cross Biotech Pty Ltd. Production of proteins in active forms
US5266205A (en) * 1988-02-04 1993-11-30 Battelle Memorial Institute Supercritical fluid reverse micelle separation
US5637566A (en) * 1988-08-24 1997-06-10 Southern Cross Biotech Pty. Ltd. Method of improving carcass quality by administering growth hormone
US5136027A (en) * 1989-05-02 1992-08-04 Abbott Laboratories Method for renaturing proteins in the presence of alkyl sulfate detergents
EP0444441B1 (en) * 1990-03-01 1996-09-25 Hewlett-Packard Company Minimizing eluate band widths in liquid chromatography
US5530100A (en) * 1990-05-07 1996-06-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Methods for purification of recombinantly produced proteins
EP0529201B1 (en) * 1991-08-26 1997-09-24 Hewlett-Packard Company Chromatographic method with micellar on-column enrichment
US5252216A (en) * 1992-03-24 1993-10-12 Smithkline Beecham Corporation Protein purification
AU729415B2 (en) 1996-07-12 2001-02-01 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
ZA9711733B (en) 1996-12-31 1998-07-01 Monsanto Co Method for solubilization and naturation of somatotropins
US20020052026A1 (en) * 1997-10-08 2002-05-02 Steven M. Vicik Methods of refolding proteins
DE69943205D1 (de) 1998-08-06 2011-03-31 Mountain View Pharmaceuticals Peg-uricase Konjugate und Verwendung davon
US7319021B2 (en) * 2002-11-01 2008-01-15 Promega Corporation Cell lysis composition, methods of use, apparatus and kit
DE10309691B4 (de) 2003-02-28 2018-10-04 Hans-Knöll-Institut für Naturstoff-Forschung e.V. Gewinnung von löslichen Proteinen aus der Biomasse rekombinanter Mikroorganismen
KR101304289B1 (ko) 2005-04-11 2013-09-12 새비언트 파마수티컬즈 인크. 유레이트 옥시다아제의 변이형 및 이의 용도
TWI418564B (zh) * 2005-04-11 2013-12-11 Savient Pharmaceuticals Inc 利用陽離子界面活性劑之蛋白質純化
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US9534013B2 (en) * 2006-04-12 2017-01-03 Horizon Pharma Rheumatology Llc Purification of proteins with cationic surfactant
MX2007012547A (es) 2005-04-11 2008-03-11 Savient Pharmaceuticals Inc Formas variantes de urato oxidasa y uso de las mismas.
WO2006125452A1 (en) * 2005-05-23 2006-11-30 Universite De Geneve Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant
EP1970706B1 (en) * 2005-12-14 2015-08-19 Denka Seiken Co., Ltd. Immunochromatography detection of multidrug-resistant staphylococcus and diagnostic kit
WO2008034016A2 (en) * 2006-09-15 2008-03-20 Foldrx Pharmaceuticals, Inc. Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins
US9706787B2 (en) * 2007-10-05 2017-07-18 Advance International Inc. Systems and methods for deriving protein powder
US8663725B2 (en) * 2007-10-05 2014-03-04 Advance International Inc. Method for deriving a high-protein powder/ omega 3 oil and double distilled water from any kind of fish or animal ( protein)
US9377454B2 (en) 2009-06-25 2016-06-28 Crealta Pharmaceuticals Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
SG11201407812SA (en) * 2012-05-31 2014-12-30 Agency Science Tech & Res Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives
US9826757B2 (en) 2013-03-15 2017-11-28 Advance International Inc. Automated method and system for recovering protein powder meal, pure omega 3 oil and purified distilled water from animal tissue
JP6147340B2 (ja) * 2013-05-29 2017-06-14 Jsr株式会社 洗浄用組成物、タンパク質精製方法、及びタンパク質
SG11201607001PA (en) 2014-02-27 2016-09-29 Agency Science Tech & Res Methods for reducing chromatin content in protein preparations by treatment with alkyl cations
CA2920789C (en) 2015-06-04 2021-05-18 Advance International, Inc. Improved methods and systems for recovering protein powder and natural omega-3 oil from animal tissue
JP2019535819A (ja) 2016-11-11 2019-12-12 ホライゾン ファーマ リューマトロジー リミテッド ライアビリティ カンパニーHorizon Pharma Rheumatology Llc プレドニゾンおよびウリカーゼ分子の併用療法ならびにその使用
JP6984828B2 (ja) * 2017-11-22 2021-12-22 学校法人東京薬科大学 凝集タンパク質の再生剤およびこれを用いた凝集タンパク質の再生方法
WO2020160322A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)
WO2020160325A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2829089A1 (de) * 1977-07-13 1979-02-01 Sandoz Ag Subunit-vakzine
US4462940A (en) * 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
US4659568A (en) * 1985-02-27 1987-04-21 American Cyanamid Company Process for solubilization, purification and characterization of protein from insoluble protein aggregates or complexes and compositions of matter therefrom
US4656255A (en) * 1985-09-09 1987-04-07 International Minerals & Chemical Corp. Protein recovery
WO1988000942A2 (en) * 1986-07-28 1988-02-11 Allied Corporation Sulfonate benzotriazoles and their use in polyamide

Also Published As

Publication number Publication date
DK171331B1 (da) 1996-09-09
AU597924B2 (en) 1990-06-14
ATE76878T1 (de) 1992-06-15
NO864990L (no) 1987-06-12
DE3685562D1 (de) 1992-07-09
EP0226448A2 (en) 1987-06-24
MY101204A (en) 1991-08-17
EP0226448B1 (en) 1992-06-03
GR3004903T3 (enExample) 1993-04-28
CN86108729A (zh) 1987-10-21
NZ218586A (en) 1989-07-27
CA1281849C (en) 1991-03-19
AU6687486A (en) 1987-06-18
JPS62223192A (ja) 1987-10-01
NO864990D0 (no) 1986-12-10
DK592186A (da) 1987-06-12
EP0226448A3 (en) 1989-01-11
DE3685562T2 (de) 1992-12-24
US4797474A (en) 1989-01-10
JPH0660198B2 (ja) 1994-08-10
DK592186D0 (da) 1986-12-10

Similar Documents

Publication Publication Date Title
ES2032194T3 (es) Solubilizacion de agregados proteicos.
ATE114156T1 (de) Herstellung von proteinen in aktiver form.
DE3484616D1 (de) Enzymwiderstandsfaehige immunomodulatorische peptide.
ATE292473T1 (de) Thymosin beta 4 stimuliert wundheilung
ATE112687T1 (de) Mutanten des hiv-1 hüllproteins mit fehlenden hypervariabelen domänen.
BR0009964A (pt) Peptìdios artificiais com atividade desuperfìcie e sua utilização na preparação de surfactante artificial
ES2136599T3 (es) Tratamiento de las heridas utilizando peptidos biologicamente activos.
ATE120091T1 (de) Vip-konjugate und deren aktive fragmente mit hydrophoben anteilen und topische zuberetungen zur verwendung in der behandlung männlicher impotenz.
SE8602405D0 (sv) Ny formulering
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
ATE125268T1 (de) Säureempfindliche subeinheit eines insulinähnlichen wachstumfaktors-bindeprotein- komplexes.
AR034226A2 (es) Procedimiento perfeccionado para estabilizar proteinas.
FR2662698B1 (enExample)
NZ335385A (en) Active hedgehog conjugate, process for its production and use
ES2146214T3 (es) Vacunas para actinobacillus pleuropneumoniae.
TR199802648A2 (xx) Gen tedavisi i�in n�klein asit yap�lar�.
IT1232318B (it) Composizioni ad uso topico contenenti acidi nucleici depolimerizzati per la cosmesi della pelle e del corpo.
DE3775389D1 (de) Verwendung von interleukin-1-proteinen gegen arthritis.
ES2013500A6 (es) Metodo para producir una variante de secuencioa de aminoacidos de un activador de plasmionogeno.
EP0315118A3 (en) Dna coding for endothelin and use thereof
BR0102085A (pt) Material de eletrodo-positivo reduzido em célulaseletroquìmicas, processo para sua preparação,seu uso, célula eletroquìmica, bem como uso deóxido de estanho reduzido
BR9612422A (pt) Pseudo-partìculas virais recombinantes, composição, utilização de pseudo-partìculas, e, processo de estimulação in vitro de respostas t citotóxicas de linfócitos provenientes de indivìduos atingidos por infecções virais ou tumorais.
BR9914466A (pt) "contortrostatina (cn) e métodos para seu uso na prevenção da metástase e outras condições"
DE3865642D1 (de) Pharmazeutische zubereitung zur cholelitholyse.
ATE4196T1 (de) Ovulation stimulierende peptide und deren pharmazeutische zusammensetzungen.